# Editorial prompt for: ADENOSINE

Paste everything below this line into Claude.ai or ChatGPT.
Save the model's JSON response as `adenosine.json` in this same folder.
When you've collected all responses, run:

    inci-pipeline import-editorial

---

You are an editorial writer for a skincare ingredient database. You are summarizing peer-reviewed evidence for a general audience.

Ingredient: ADENOSINE
Declared functions (from EU CosIng): (unspecified)
Restricted in EU: no
Restricted in US: no

Source abstracts (from PubMed):
PMID: unknown
Title: Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture.
Year: 2010
Abstract: Acupuncture is an invasive procedure commonly used to relieve pain. Acupuncture is practiced worldwide, despite difficulties in reconciling its principles with evidence-based medicine. We found that adenosine, a neuromodulator with anti-nociceptive properties, was released during acupuncture in mice and that its anti-nociceptive actions required adenosine A1 receptor expression. Direct injection of an adenosine A1 receptor agonist replicated the analgesic effect of acupuncture. Inhibition of enzymes involved in adenosine degradation potentiated the acupuncture-elicited increase in adenosine, as well as its anti-nociceptive effect. These observations indicate that adenosine mediates the effects of acupuncture and that interfering with adenosine metabolism may prolong the clinical benefit of acupuncture.

PMID: unknown
Title: Adenosine uptake inhibitors.
Year: 2004
Abstract: Adenosine is a purine nucleoside and modulates a variety of physiological functions by interacting with cell-surface adenosine receptors. Under several adverse conditions, including ischemia, trauma, stress, seizures and inflammation, extracellular levels of adenosine are increased due to increased energy demands and ATP metabolism. Increased adenosine could protect against excessive cellular damage and organ dysfunction. Indeed, several protective effects of adenosine have been widely reported (e.g., amelioration of ischemic heart and brain injury, seizures and inflammation). However, the effects of adenosine itself are insufficient because extracellular adenosine is rapidly taken up into adjacent cells and subsequently metabolized. Adenosine uptake inhibitors (nucleoside transport inhibitors) could retard the disappearance of adenosine from the extracellular space by blocking adenosine uptake into cells. Therefore, it is expected that adenosine uptake inhibitors will have protective effects in various diseases, by elevating extracellular adenosine levels. Protective or ameliorating effects of adenosine uptake inhibitors in ischemic cardiac and cerebral injury, organ transplantation, seizures, thrombosis, insomnia, pain, and inflammatory diseases have been reported. Preclinical and clinical results indicate the possibility of therapeutic application of adenosine uptake inhibitors.

PMID: unknown
Title: The role of adenosine in epilepsy.
Year: 2019
Abstract: Adenosine is a well-characterized endogenous anticonvulsant and seizure terminator of the brain. Through a combination of adenosine receptor-dependent and -independent mechanisms, adenosine affects seizure generation (ictogenesis), as well as the development of epilepsy and its progression (epileptogenesis). Maladaptive changes in adenosine metabolism, in particular increased expression of the astroglial enzyme adenosine kinase (ADK), play a major role in epileptogenesis. Increased expression of ADK has dual roles in both reducing the inhibitory tone of adenosine in the brain, which consequently reduces the threshold for seizure generation, and also driving an increased flux of methyl-groups through the transmethylation pathway, thereby increasing global DNA methylation. Through these mechanisms, adenosine is uniquely positioned to link metabolism with epigenetic outcome. Therapeutic adenosine augmentation therefore not only holds promise for the suppression of seizures in epilepsy, but moreover the prevention of epilepsy and its progression overall. This review will focus on adenosine-related mechanisms implicated in ictogenesis and epileptogenesis and will discuss therapeutic opportunities and challenges.

PMID: unknown
Title: Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.
Year: 2022
Abstract: The immunosuppressive effect of adenosine in the microenvironment of a tumor is well established. Presently, researchers are developing approaches in immune therapy that target inhibition of adenosine or its signaling such as CD39 or CD73 inhibiting antibodies or adenosine A2A receptor antagonists. However, numerous enzymatic pathways that control ATP-adenosine balance, as well as understudied intracellular adenosine regulation, can prevent successful immunotherapy. This review contains the latest data on two adenosine-lowering enzymes: adenosine kinase (ADK) and adenosine deaminase (ADA). ADK deletes adenosine by its phosphorylation into 5'-adenosine monophosphate. Recent studies have revealed an association between a long nuclear ADK isoform and an increase in global DNA methylation, which explains epigenetic receptor-independent role of adenosine. ADA regulates the level of adenosine by converting it to inosine. The changes in the activity of ADA are detected in patients with various cancer types. The article focuses on the biological significance of these enzymes and their roles in the development of cancer. Perspectives of future studies on these enzymes in therapy for cancer are discussed.

PMID: unknown
Title: [Purinergic neuromodulation].
Year: 1990
Abstract: Adenosine and its nucleotides participate in the regulation of various functions in the nerve system and in some internal organs. These purines are released from a variety of nervous and non-nervous cellular sources. Adenosine receptors are situated extracellular; they mediate some effects of the adenosine and are coupled negatively (A1 adenosine receptors) and positively (A2 adenosine receptors) to adenylate cyclase. The physiological effects of adenosine are inhibitory; they are exerted synaptically and extrasynaptically. The main synaptic modulatory effect is the presynaptic inhibition of the excitatory and inhibitory neurotransmitters release. Postsynaptically adenosine modulate the answer to neurotransmitter effects. ATP functions probably as co-transmitter or transmitter in the non-adrenergic non-cholinergic autonomic neurons. Neuromodulatory and the majority of metabolic adenosine effects are antagonized by methylxanthines. Exogenous substances can influence the molecular mechanisms of adenosine systems; some of the induced pharmacodynamical effects could be of therapeutic interest. Drug-interactions with adenosine systems can cause side effects.

- `what_it_does`: one sentence (under 120 chars) describing the ingredient's primary role in a formulation.
- `summary_short`: 2–3 sentences (under 400 chars), readable by a non-expert, suitable for a decode result. Include the most useful single fact a user would want to know at a glance.
- `summary_long`: 3–6 paragraphs in Markdown. Cite at least one source by PMID inline using `[PMID:12345678]` notation. Cover: mechanism, evidence quality, typical concentrations if mentioned, irritation/safety notes, common pairings or conflicts.
- `quick_facts`: array of 3–6 consumer-useful short bullet strings (<80 chars each). Examples: "Water-soluble", "Best below 10% concentration", "Pairs poorly with vitamin C".

Constraints:
- Never invent claims. If the abstracts don't support a claim, omit it.
- Never assign an overall rating ("great", "bad", etc.) — that's reserved for human curators.
- If evidence is thin, say so plainly in `summary_long`.

Write for skincare consumers, not researchers. Avoid evidence-audit language such as “typical concentration not provided,” “the abstracts do not mention,” or “no specific conflicts were identified.” Only mention a limitation if it changes how a user should interpret safety, effectiveness, or product use. Otherwise, leave that detail out.

